Biogen Raises Annual Guidance Despite Q3 Earning Impacted By Biosimilar Competition
- Biogen Inc posted Q3 sales of $2.51 billion, beating the consensus of $2.47 billion, down 10% Y/Y and 8% at constant currency (CC).
- Multiple sclerosis revenue, including royalties on sales of Ocrevus, of $1.62 billion decreased by 11% (down 9% CC).
- Spinraza's revenue of $431 million decreased by 3% at actual currency (increased by 2% at CC).
- Aduhelm generated sales of $1.6 million in Q3, compared to $0.3 million a year ago.
- Biosimilars' revenue of $188 million decreased by 7% versus the prior year at actual currency and increased by 4% at constant currency.
- Multiple sclerosis drug Tysabri sales are down 3.3% to $505.5 million.
- Adjusted EPS of $4.77 came above the consensus of $4.16.
- Guidance: Biogen raised FY22 sales guidance to $10-$10.15 billion, up from prior guidance of $9.9-$10.1 billion and the consensus of $10.01 billion.
- The company expects adjusted EPS of 16.50-$17.15, up from $15.25-$16.75 compared to the consensus of $16.49.
- The increase in guidance is driven primarily by better-than-expected topline performance and continued cost management.
- The guidance assumes continued declines in Rituxan revenue due to biosimilar competition and a continued erosion of Tecfidera revenue due to generic entry.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.